Order of the National Green Tribunal in the matter of News Item titled "2 killed in blast at illegal cracker unit in Thanjavur appearing in The Hindu dated 19.05.2025". The application is registered suo-motu on the basis of the news item titled 2 killed in blast at illegal cracker unit …
Despite clinical trials coming under scrutiny, nothing much has changed on ground as many irregularities continue to exist. While the office of the Drugs Controller General of India (DCGI) is still struggling to accumulate data, compensation had been paid only in 50 per cent of the clinical trial death cases …
In an evaluation of medicines approved by the European Medicines Agency 2000 to 2010, Ruben Duijnhoven and colleagues find that the number of patients evaluated for medicines approved for chronic use are inadequate for evaluation of safety or long-term efficacy.
Taking suo motu cognisance of a letter seeking action against renowned pharmaceutical companies for looting cancer patients by printing inflated maximum retail price (MRP) on medicines, the Punjab and Haryana High Court today put the state of Punjab on notice. The Division Bench of Chief Justice Arjan Kumar Sikri and …
Agovernment panel has proposed that prices of patented medicines be based on the country’s per capita income, a move that would substantially reduce prices of costly drugs made by global pharmaceutical firms. The proposal, which seeks the input of other government agencies as well as industry groups, could provoke the …
Man-made chemicals in everyday products are likely to be at least the partial cause of a global surge in birth deformities, hormonal cancers and psychiatric diseases, a U.N.-sponsored research team reported on Tuesday. These substances, dubbed EDCs, could also be linked to a decline in the human male sperm count …
Forms four expert panels to draft permission guidelines Following more than 2,200 deaths in clinical trials in the past five years, the government has finally set up four expert committees to streamline approvals and evolve standard operating procedures for marketing of drugs in India, which are discovered abroad. The move …
The rules notified by the government for compensating clinical trial victims have failed to address the concerns raised by patient groups and health activists. The norms, which have come into place after repeated slamming of the government by the Supreme Court, do not specify any quantum of compensation that pharmaceutical …
The National Human Rights Commission (NHRC) on Thursday issued a notice to the Union Health Ministry after receiving information that three government hospitals committed illegal drug trials on nearly 3,500 children in the past five years. According to NHRC, a notice was sent to the Secretary of Union Ministry of …
The National Human Rights Commission (NHRC) on Thursday issued a notice to the Union Health Ministry after receiving information that three government hospitals committed illegal drug trials on nearly 3,500 children in the past five years. According to NHRC, a notice was sent to the Secretary of Union Ministry of …
Companies failing to pay up within the stipulated time may face suspension of trials and even a permanent ban Pharma companies sponsoring clinical trials in India would now need to compensate volunteers in cases of trial-related deaths or injuries. Firms and clinical research organisations failing to pay up, could face …
The government has finally stepped in to curb the practice of paying variable or no compensation by pharma firms for deaths due to clinical trials. It has notified rules for granting relief in case of Serious Adverse Events like death or injuries. The grant will depend on categories fixed by …
In a move that will go a long way in ensuring the safety of subjects who participate in clinical trials in India, the government has notified procedures whereby compensation will be awarded in case of death or injury suffered by persons participating in the trials. Hitherto, there was no rule …
Issuing licence is totally compliant with multilateral agreements: Sharma India, on Wednesday, conveyed to the U.S. that it had not violated any multilateral trade agreement by issuing compulsory licence for Bayer’s patented anti-cancer drug Nexavar to a local firm so as to make it affordable. It also asserted that such …
The Lahore Chamber of Commerce and Industry (LCCI) will establish Green Productivity Cell that would work in collaboration with EU Switch Asia Programme and SMEDA to increase production efficiency and reduce wastage in targeted sectors, including textile, food processing and pharmaceutical industry. A decision to this effect was taken at …
Cyrus Poonawalla?s Serum Institute of India to enter injectable polio vaccine market, undercut Glaxo Billionaire Cyrus Poonawalla, founder of the world’s biggest maker of vaccines, will slash the price of polio immunisation and introduce shots for diarrhea and pneumonia, undercutting Pfizer and GlaxoSmithKline (GSK). Poonawalla, who set up the Serum …
The government's move to issue compulsory licences (CLs) for three more patented cancer drugs is a jolt to multinational pharmaceutical companies. The plan is to issue CLs for Trastuzumab (or Herceptin, used for treating breast cancer), Ixabepilone (used for chemotherapy in breast cancer treatment) and Dasatinib (or Sprycel, for leukaemia). …
Each of the 3 drugs— Dasatinib Trastuzumab & Ixabepilone—costs 1L for a month’s dose The government has appointed a panel to look into issues related to compulsory licensing of drugs and whether cheaper versions of cancer medicines Trastuzumab, Ixabepilone and Dasatinib can be launched under the provision, a person with …
Firms, foreign and Indian, reiterate they follow the rules fully earlier, SC had rapped govt for gaps in law and enforcement, including on compensation Despite courts slamming the authorities over the monitoring of clinical trials in the country, the number of deaths caused by the adverse impact of drugs in …
MNC Body Backs MCI Guidelines Banning All Kinds Of Gifts To Doctors In Clinical Trial Mumbai: The noose may get tighter for the pharma industry. After facing flak for illegal drug trials, and unethical marketing practices, the pharma industry seems to be pulling up its socks. In a significant development, …
The Supreme Court on Monday issued notice to the Centre on a public interest writ petition against licensing of and trials with the unproven human papillomavirus (HPV) vaccines, ostensibly to treat cervical cancer. The petition, by Kalpana Mehta and other health activists, cited the Drugs Controller-General of India (DCGI), the …
